摘要
目的:调查三阴性乳腺癌术后辅助化疗三种方案的临床应用情况,制订药学监护点。方法:收集我院2009年12月至2017年5月168例三阴性乳腺癌患者,化疗方案选用TAC、TP或AC→T方案,对三组患者进行具体分析。结果:胃肠道反应:TAC组Ⅰ度8例,Ⅱ度28例;AC→T组Ⅰ度4例,Ⅱ度100例;Ⅲ度4例;TP组Ⅱ度20例,Ⅲ度4例。骨髓抑制:TAC组Ⅱ度32例,Ⅲ度4例;AC→T组Ⅱ度92例,Ⅲ度16例;TP组Ⅱ度20例,Ⅲ度4例。三组不同化疗方案TNBC患者的胃肠道反应、骨髓抑制的发生情况比较差异均无统计学意义(P>0.05)。一年肿瘤无进展生存率:TAC 88.9%;AC→T 92.6%;TP 100%,平均化疗费用:TAC20686.94±199.87元;AC→T 19470.83±150.988元;TP 12895.42±276.341元,平均住院天数为8.808±0.2792天;10.213±0.2429天;10.958±0.3782天。结论:在TAC、TP和AC→T方案中,TP方案治疗三阴性乳腺癌的临床疗效可,副反应少,费用少,是较优选的治疗方案。
Objective:To investigate the clinical application of three kinds of postoperative adjuvant chemotherapy(TAC,TP,AC→T)for the three negative breast cancer,and make pharmaceutical care point.Methods:168 cases of three negative breast cancer patients admitted in our hospital and given TAC TP,or AC→T chemotherapy regimens from December 2009 to May 2017,were collected and analyzed.Results:Gastrointestinal reactionⅠandⅡwere found in 8 and 28 cases of TAC group,gastrointestinal reactionⅠ,ⅡandⅢwere found in 4,100 and 4 cases of AC→T group,gastrointestinal reactionⅡandⅢwere found in 20 and 4 cases in the TP group.Bone marrow suppressionⅡandⅢwere found in 32 and 4 cases of TAC group,92 and 6 cases of AC→T group,20 and 4 cases in the TP group.No significant difference was found in the incidence of gastrointestinal reaction and bone marrow suppression between TNBC patients undergoing different chemotherapy regimens(P>0.05).The tumor progression-free survival rate was 88.9%in TAC group,92.6%in the AC→T group,100%in the TP group.The average chemotherapy costs were 20686.94±199.87,19470.83±150.988 and12895.42±276.341 yuan in the TAC,AC→T and TP group,the average hospitalization days were 8.808±0.2792,10.213±0.2429,10.958±0.3782 days in the TAC,AC→T and TP group.Conclusions:Among TAC,TP and AC→T chemotherapy regimens,TP chemotherapy regimen was most effective in the treatment of TNBC with less adverse reactions and lower treatment costs.
作者
刘屹
丰航
许凡凡
张鑫雨
何恒
张鹏
朱亚宁
LIU Yi;FENG Hani;XU Fan-fan;ZHANG Xin-yu;HE Heng;ZHANG Peng;ZHU Ya-ning(Department of oncology,Shaanxi People's Hospital,Xi'an,Shaanxi,710068,China;Department of pharmacology,Xi'an,Shaanxi,710068,China;Fourth Cadet Brigade,Air Force Medical University,Xi'an,Shaanxi,710032,China)
出处
《现代生物医学进展》
CAS
2019年第5期880-885,937,共7页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(NSFC 81402012)
陕西省自然科学基金项目(2015JQ8321)
关键词
三阴性乳腺癌
术后辅助化疗
化疗方案
药学服务
Triple negative breast cancer(TNBC)
Postoperative adjuvant chemotherapy
Chemotherapy regimens
Pharmaceutical service
